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2019 UGP GRANT AWARD FINAL REPORT 
 
Title: UGP2019: Investigating the Mechanism Responsible for the Effect of Behavioral Cough 
Therapy  
Principal Investigator: Laurie Slovarp, PhD 
 
 
The following specific aim was completed:  
 
Demonstrate feasibility and collect preliminary data to quantify expression of TRPV1 receptors 
in the nose and throat pre and post BCT in patients with refractory chronic cough (RCC). 
Minimally invasive brush biopsies, obtained from the nose and larynx will be analyzed using either 
qPCR for TRPV1 mRNA expression. We propose to analyze both nasal and laryngeal epithelial cells 
to determine if they respond similarly to behavioral cough therapy (BCT) in patients with RCC. The 
specific purpose of meeting this aim is to strengthen an R15 or R21 grant proposal that will be 
submitted within six months of completion of the UGP small grant period. 
 
 
Protocol Revisions:  
 
1. The protocol was modified after discovering brush biopsies yielded so little tissue it was unlikely 
we would get reliable results with qPCR. I then amended the IRB to allow for forceps biopsies 
from the epiglottis. I removed the nasal biopsy aspect of the protocol because a forceps biopsy 
from the nose would be too uncomfortable and result in too much bleeding. The IRB amendment 
for this protocol change was approved on 6/25/19.  
2. The original protocol included cough frequency testing with surface EMG (sEMG) technology 
with the assistance of Dr. Matt Bundle.  The purpose of testing sEMG as a cough frequency 
monitor on these participants was to determine feasibility for use in future research.  This protocol 
was amended when I discovered the availability of a smart medical wearable cough respiratory 
monitoring device that includes the capability of monitoring cough. The device is called the 
Automated Device for Asthma Monitoring and Management (ADAMM) and is made by 
Healthcare Originals, Inc. (HCO). A collaboration agreement with HCO was signed on 11/22/19. 
The agreement included the use of 6 ADAMM devices to test its validity as a cough frequency 
monitor on patients with chronic refractory cough. 
3. The study was halted in March 2020 due to the COVID-19 pandemic.  At that point we had two 
participants who were due for their post-treatment biopsies. I submitted an amendment to the IRB 
in May 2020 to request permission to obtain those two additional biopsies with extra precautions 
taken to prevent COVID-19 transmission. That amendment was approved on 6/10/20.  
 
Budget Revisions:  
 
1. A request was made to pay Fred Rhoderick to complete the qPCR analyses on the biopsies 
because Dr. Sarjubhai Patel was unavailable to complete them summer 2020 due to research 
related to COVID-19. This request was approved; however, Mr. Rhoderick ended up 
volunteering to donate his time.  
2. A request was made to purchase a lab fume with HEPA filter and UV light to allow my team to 
prepare capsaicin dilutions (for a different, but related, project) in my lab in the Curry Health 
Center rather than in the Skaggs building. That request was approved on 8/6/20. The fume hood 





1. Laryngeal biopsies were collected from four participants before and after behavioral cough 
therapy.  I obtained a pre-treatment biopsy on one additional participant but was unable to obtain 
the post-treatment biopsy because by the time the IRB approved me to resume the study after the 
COVID-19 shutdown, that participant had moved out of state.  
 
Fred Rhoderick completed qPCR on the biopsies. Pre and post-treatment biopsies for three 
participants were viable for qPCR. The results did not support the hypothesis as they showed a 
increase in TRPV1 gene expression in the only participant who responded to therapy and the 
hypothesis was that the gene expression would decrease. Minimal change in gene expression 
was found in the other two participants, who did not improve with therapy. These results need to 
be interpreted with caution as the RNA integrity of each of the samples was low, which can 
reduce the reliability of the analysis. A larger data set is needed to draw any conclusive 
conclusions about the feasibility of this protocol to determine change in TRPV expression 
following BCT.  
 
2. Data has been collected on six participants for testing validity of the ADAMM device as a cough 
frequency monitor for patients with refractory chronic cough. Data collection was complete in 
July 2020 but the data is transferred to a server at HCOs via the internet. HCOs then sends the 
data for my team to analyze. The full data set was received on 9/8/20. We have analyzed the data 
on two participants, which has resulted in sensitivity of less than 50%. HCOs has discovered a 
problem with the way some of the data was processed which resulted in some of the data being 
lost. They believe they are able to correct the problem and we will be re-launching the study in 
October 2020.  I anticipate a new data set will be collected by the end of 2020. 
 
Future Grant Proposal: 
 
I had planned to submit an R01 proposal for a multi-site clinical trial study of cough desensitization 
therapy (a novel treatment for RCC that I have completed pilot testing on), which may include collecting 
pre and post biopsies and use of the ADAMM device as a cough frequency monitor, in February 2021.  
Due to the delay caused by COVID-19, I am now planning to submit the R01 in June 2021. The multi-
site team has been established with researchers from University of Utah, University of Colorado, and 
Emory University.  
 
